Management Presentation
confidently live life with ease
1
confidently live life with ease Management Presentation 1 - - PowerPoint PPT Presentation
confidently live life with ease Management Presentation 1 Forward-Looking Statements These statements involve known and unknown risks, uncertainties and other factors that may This presentation contains certain forward-looking statements cause
Management Presentation
1
In some cases, you can identify forward-looking statements by the words “expect,” “intend,” “target,” “plan,” “estimate,” “predict,” “opportunity,” and “continue,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements include statements about future demand for our Eversense™ System and future products, if any, that we may develop; the growth of the CGM market; the factors that we believe drive demand for our Eversense™ System and our ability to sustain such demand; the size of the market and competitive landscape for our Eversense™ System; the initiation, timing, progress and results of our clinical trials; our plans for the Eversense™ System and our expectations about completion of its development and the timing of the submission for regulatory approval by the FDA, and the timing for receiving such approvals; our enhancement of the Eversense™ System, including the extension of sensor life and improvements in accuracy; launch of the Eversense™ System in the United States and European countries; expected long-term gross profit margins; our plans for pursuing coverage and reimbursement for our Eversense™ System; our ability to protect and enforce our intellectual property rights; and anticipated trends and challenges in our business and the market in which we operate. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward- looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this presentation, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that we may not achieve greater market acceptance of our Eversense™ System; the risk that we may not be able to establish sales and marketing capabilities in order to meet demand for our Eversense™ System; risks associated with competition in the diagnostics industry; risks associated with the performance of our Eversense™ System; the risk that we may not receive regulatory clearance for our Eversense™ System in the United States; the risk that we may not be able to comply with extensive ongoing regulatory requirements; risks associated with reliance on a limited number of suppliers; the risk that we may not be able to successfully develop or introduce new or other applications of our technology at all or in a timely manner; the risk that we may not be able to maintain and expand coverage and reimbursement from health insurers and other third-party payers; risks associated with limited patent protection; the risk that we may not successfully manage our growth; and risks associated with reliance on outside financing to meet capital requirements. For further information regarding these risks, uncertainties and other factors you should read the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2015, our Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 and our other filings we make with the Securities and Exchange Commission from time to time. Any forward-looking statements speak only as of the date of this presentation. We undertake no
information, future events or otherwise. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.
This presentation contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward- looking statements.
Develop and commercialize transformative glucose monitoring products.
Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United States.
3
50 100 150 200 250 300 350
14.00 22.00 0.00 2.00 4.00 6.00 8.00 10.00
Time
Glucose Concentration
(mg/dL)
Target Range
HYPOGLYCEMIA HYPERGLYCEMIA
Eversense Glucose Readings SMBG SMBG SMBG SMBG 8AM 12PM 4PM 8PM 12PM 4AM
Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United States.
4
2 4 6 8 10
2015 2020
Europe U.S.
Millions of Patients
Europe U.S.
$0.7 $2.5 $6.5 $3.3 $3.5 $5.8
$0 $1 $2 $3 $4 $5 $6 $7 $8
CGM* Insulin Pumps SMBG
Revenue In Billions
2015 2020 Est. 2015 2020 Est. 2015 2020 Est. ~35 – 40% CAGR ~8% CAGR ~(2%) CAGR
CGM fastest growing segment
Intensively Managed Population
Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United States.
5
Discomfort when wearing CGM Problems inserting sensor Problems with adhesive holding sensor on the skin Accuracy Sensor skin reactions
Real-Time Continuous Glucose Monitoring Among Participants in the TID Exchange Clinic Registry
Wong J.C et al, Diabetes Care 2014;37:2702–2709 | DOI: 10.2337/dc14-0303
top 5 reasons why people discontinue CGM...
Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United States.
6
Sensor Smart Transmitter Mobile App Sensor that lasts up to 180 days No weekly sensor insertion No open wound
Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United States.
Removable and rechargeable On-body vibe alerts Gentle-on-skin adhesive No extra device to carry iOS and Android platform Alarm settings & reports
7
Non-enzymatic, fluorescence based measurement Simple in-office procedure – less than 5 mins Best-in-class accuracy Tested in over 900 sensors in 500 patients, 100,000 sensor wear days no weekly sensor insertion no open wound no sensor wasted when transmitter removed Lasts up to 180-days without removing
Polymer Hydrogel Biocompatible Encasement NFC Antenna Optical Interface
Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United States.
8
Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United States.
9
Email PDF report to caregiver
Reports Directly on App Predictive Low/High Glucose Alerts & Rate of Change Alerts Readings on Applewatch Remote Monitoring with Eversense Now
Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United States.
10
16,000+ paired data points, 2,000,000+ sensor glucose readings
Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United States.
11
Glucose range
Throughout 90-day use
accuracy
multi-center investigation
90 days in upper arm
glucose algorithm
Ease
No Pain / Discomfort Want to be Inserted Again Would Like to Use Every Day
“The device shows both glycemic value and its trend and leads to hypoglycemia disappearance… very easy to use.”
– Romanian study participant (2014)
“Significant reduction of hypoglycemia due to early warning → safety gain → life quality ↑↑↑ !!!! I have exercised much more.”
– German study participant (2015)
“When you work a lot and are on the move constantly, it is gold worth not having to take blood samples. It is extra security to have the alarm directly on the body.”
– Sweden user (July 2016)
“My patient was in near tears when the study ended and she had to give back the device.”
– Jort Kropff, MD Amsterdam Medical Center
Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United States.
12
“One of the features of endocrinology that appealed to me is the relative absence
performing the sensor insertion, I realized that I no longer fear procedures. I felt very comfortable after the first two sensors.”
Diablo Clinical Research, Walnut Creek, California
“It was surprising how easy the insertion procedure was.”
Institute for Diabetes Technology, Ulm, Germany
“I don’t understand why some would think implanting a sensor would be difficult without having any first hand knowledge of the procedure. We’re transitioning into ‘interventional endocrinologists’ to meet the needs of our patients.”
AMCR Institute, Escondido, California
Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United States.
13
14
Utilize experienced distributors OUS
Build strong direct sales force in US Target key clinic and patient base
Total price reflects reimbursement to endos Reduced co-pays with bi-annual sensor purchase Reduce number
to purchase CPT category III codes issued
Medical benefit Positive coverage decision for CGM Product introductions to grow share and market
Strong product pipeline Awareness and training programs
Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United States.
Selling in Sweden June 2016 Launch in Norway, Denmark 4Q16 Launch in Germany September 2016 Launch in Italy, Netherlands 4Q16
Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United States.
15
US Launch (2017) Europe Launch (2016) Europe Launch Target (2017 future markets)
Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United States.
16
Sales Force Role By Activity and Segment
Payers Endos Diabetes Eds KOLs Patients Sales Call Sensor Training
Key Acct Mgrs N/A Sales Rep Clinical Training Mgr Sales Rep Clinical Training Mgr Sales Rep N/A
Segments Activities
Device Training By Sales, Clinic
17
Category III Codes
with insertion of implantable interstitial glucose sensor, including system activation and patient training
glucose sensor from subcutaneous pocket via incision
glucose sensor with creation of subcutaneous pocket at different anatomic site and insertion
activation
Secured reimbursement codes for insertion procedure
Fold into existing coverage, policy or hospital tender decisions
Position product as similar to other CGMs with value-added feature set
Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United States.
18
Improve Accuracy Lower Cost Extend Duration Approve for Pediatrics Broaden Target Market Reduce Calibration Integrate with Insulin Pump
Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United States.
19
full 180 day with dosing claim
Products to grow market share
Intensively Managed Patients
MDI Patients Pump Patients Non-MDI Patients
Products to broaden target market
Insulin Using Patients and Type 2 Patients
Flash Glucose Monitoring
2 in 1
OAD Patients
Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United States.
20
2-Cal Sensor, MARD 8.8%
22:00 02:00 06:00 10:00 14:00 18:00
50 100 150 200 250 300 350 400 Glucose (mg/dL)
Target Range
Eversense Glucose Readings Lab Reference SMBG SMBG
1-Cal Sensor, MARD 9.5%
Glucose (mg/dL) 50 100 150 200 250 300 350 400
22:00 02:00 06:00 10:00 14:00 18:00 Target Range
SMBG Eversense Glucose Readings Lab Reference
user convenience same sensor
Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United States.
21
Implanted 180 day sensor, smartphone app, no transmitter worn Direct sensor communication with NFC- interfaced smartphone NFC-interfaced phones act as transmitter and receiver; powers and reads implanted sensor
the long-term flash glucose monitoring with no transmitter
Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United States.
22
the ultimate flexibility for your daily life
Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United States.
23
Initiated U.S. Pivotal Trial CE Mark Approval Commercial Launch
Sweden
CE Amendment Application 180 Day
2016
2016
2016
2016
Commercial Launch
Germany, Italy, Netherlands, Norway, Denmark
Complete U.S. Pivotal Trial Submit PMA Launch Gen 2 Transmitter
2016
2016
2016
2016
Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United States.
24
Management Presentation
25